1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis is a highlighted topic from NIH, not a specific funding opportunity announcement, encouraging research on rare skin diseases, including Epidermolysis Bullosa.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Projects including multidisciplinary teams of basic, translational, and clinical scientists are of particular interest. Examples of diseases of interest include Recessive Dystrophic Epidermolysis Bullosa. Confirm the full requirements in the official notice before applying.
Applications for Advancing Research into the Cause and Treatment of Rare Skin Diseases are due April 2, 2028. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Advancing Research into the Cause and Treatment of Rare Skin Diseases is funded by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) / National Center for Advancing Translational Sciences (NCATS) (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Advance from NIH SBIR Phase I to Phase II with tips on demonstrating feasibility, building a commercialization plan, and securing $1M in funding.
Read articlePAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read article